Sprycel

This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.

NICE backs BMS leukaemia drug Sprycel

NICE backs BMS leukaemia drug Sprycel. Watchdog approves blood cancer therapy for use by NHS in England and Wales. ... Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment

Latest news

Opdivo drives gain in BMS sales, but business revamp coming

BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
England's Cancer Drugs Fund: Fixing a broken system

Bristol-Myers Squibb's Sprycel (dasatinib):. for treatment of lymphoid blast crisis chronic myeloid leukamia.
Pharma condemns Cancer Drugs Fund cuts

Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Company. Drug. Indication. Bayer. Stivarga (regorafenib). Sarcoma. Bristol-Myers Squibb. Sprycel (dasatinib).
BMS shares fall on nivolumab jitters despite solid Q4 results

Leukaemia therapy Sprycel (dasatinib) had a "spectacular" year, according to BMS chief executive Lamberto Andreotti, rising 30 per cent to $365m in the last quarter.

More from news
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Interview: Harvey Berger and Timothy Clackson, Ariad

recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). “ ... The drug was then developed with the specific intention of
Intellectual property threats in the BRIC markets

of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Medical Writer, e-learning/ training, London: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer - (London, Brighton or Copenhagen): Competitive

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager – Med Comms – London: Salary TBC

Scientific Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Project Manager, Medical Communications, Oxford: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Programme Executive: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...